We congratulate the authors on the development of the VI-RADS scoring system, which is undoubtedly an important step in establishing the role of MRI in bladder cancer. Together with new techniques of endoscopic surgery like ERBT, it may bring a new era of bladder cancer therapy.
The validation process, however, should be stringent enough to properly evaluate its staging performance. ERBT and radical cystectomy specimens would be the more appropriate histological references in serving this purpose.
More studies are, however, warranted to identify its true significance in our clinical practice.